COMPANY

Taysha Gene Therapies

HQ: Dallas, TX source · tayshagtx.com ↗ · Southwest

Taysha Gene Therapies discovers, develops and commercializes gene therapies for monogenic diseases of the central nervous system (CNS). From company website Source · checked 2026-10-19

Taysha is developing an investigational gene therapy for Rett syndrome – TSHA-102 – a one-time treatment designed to address the root cause of the condition. From company website Source · 2026-10-12

Sources for this description (1)

Taysha Gene Therapies discovers, develops and commercializes gene therapies for monogenic diseases of the central nervous system (CNS).
- “Taysha Gene Therapies is singularly focused on discovering, developing and commercializing gene therapies for the treatment of monogenic diseases of the central nervous system (CNS), in both rare and large patient populations.” https://tayshagtx.com/about-us/ (2026-10-19)

Modality: Gene Therapy

Disease: rett syndrome

Keywords: gene therapy Leigh Syndrome

Location: Dallas, TX · source · Oct 15, 2026

Profile checked Oct 10, 2026

$400.0MRaised (2 yrs)4Trials (company is sponsor)

Timeline

Jun 24, 2026 Raise Follow-on offering: $200M (total, as published), announced Jun 24, 2026. Source: SEC filing. source ↗
May 8, 2026 Trial start Phase 3: Safety and Preliminary Efficacy of TSHA-102 Gene Therapy in Pediatric Females Aged >2 to <4 Years With Rett Syndrome source ↗
May 28, 2025 Raise Follow-on offering: $200M (total, as published), announced May 28, 2025. Source: SEC filing. source ↗
Dec 12, 2023 Trial start Phase 1/Phase 2: Safety and Efficacy of TSHA-102 in Pediatric Females With Rett Syndrome (REVEAL Pediatric Study) source ↗
Mar 6, 2023 Trial start 1: A Phase 1/2/3 Study of TSHA-102 Gene Therapy in Females With Rett Syndrome (REVEAL Pivotal Study) source ↗
May 4, 2022 Trial start —: A Study of the Natural Course of SURF1 Deficiency source ↗

Upcoming milestones

Nov 2, 2028 (ESTIMATED) · Phase 1/Phase 2 · Safety and Efficacy of TSHA-102 in Pediatric Females With Rett Syndrome (REVEAL Pediatric Study) · NCT06152237
2031-06 (ESTIMATED) · Phase 3 · Safety and Preliminary Efficacy of TSHA-102 Gene Therapy in Pediatric Females Aged >2 to <4 Years With Rett Syndrome · NCT07480564
2031-06 (ESTIMATED) · 1 · A Phase 1/2/3 Study of TSHA-102 Gene Therapy in Females With Rett Syndrome (REVEAL Pivotal Study) · NCT05606614

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $400.0M. Last 2 years.

Jun 24, 2026 Follow-on offering: $200M (total, as published), announced Jun 24, 2026. Source: SEC filing. source ↗
May 28, 2025 Follow-on offering: $200M (total, as published), announced May 28, 2025. Source: SEC filing. source ↗

Clinical trials (lead sponsor) 4

Record	Title	Phase	Status	Start	Primary completion
NCT07480564	Safety and Preliminary Efficacy of TSHA-102 Gene Therapy in Pediatric Females Aged >2 to <4 Years With Rett Syndrome	Phase 3	Active, not recruiting	May 8, 2026	2031-06 (estimated)
NCT05606614	A Phase 1/2/3 Study of TSHA-102 Gene Therapy in Females With Rett Syndrome (REVEAL Pivotal Study)	1	Active, not recruiting	Mar 6, 2023	2031-06 (estimated)
NCT06152237	Safety and Efficacy of TSHA-102 in Pediatric Females With Rett Syndrome (REVEAL Pediatric Study)	Phase 1/Phase 2	Active, not recruiting	Dec 12, 2023	Nov 2, 2028 (estimated)
NCT05277363	A Study of the Natural Course of SURF1 Deficiency	Not listed	Withdrawn	May 4, 2022	May 4, 2022 (actual)